RenovoRx Phase III Trial Hits Enrollment Milestone, Data Expected 2027
Event summary
- RenovoRx's TIGeR-PaC Phase III trial has randomized over 100 patients, nearing the protocol's requirement of 114.
- The trial is currently on track for enrollment completion in the first half of 2026, with final data expected in 2027.
- Select cancer centers are now utilizing RenovoRx’s RenovoCath device as a standalone drug-delivery device.
- The independent data monitoring committee (DMC) has recommended continuation of the trial in both interim analyses.
The big picture
RenovoRx's progress in the TIGeR-PaC trial represents a key step in validating its novel drug-device combination approach for locally advanced pancreatic cancer. The company’s strategy of leveraging the FDA-cleared RenovoCath device for both standalone sales and targeted drug delivery positions it within a growing market for minimally invasive oncology therapies, but success depends on demonstrating clinical benefit and navigating regulatory hurdles.
What we're watching
- Regulatory Risk
- The FDA’s review of IAG under the 21 CFR 312 pathway presents a significant hurdle, and any disagreements with RenovoRx’s data interpretation could delay or impact approval.
- Clinical Efficacy
- The interim analyses have been positive, but the ultimate success hinges on whether the final data demonstrates statistically significant efficacy in minimizing therapy toxicities compared to standard intravenous therapy.
- Commercialization
- While initial commercial purchases of RenovoCath are encouraging, the company’s ability to scale revenue generation and potentially secure a commercial partner will be crucial for long-term viability.
Related topics